Skip to main content
Donate
Login
IASLC's 50th Anniversary
IASLC's 50th Anniversary
History
Support The Mission
Support The Mission
Partners for Thoracic Cancer Care
Legacy Society
IASLC Global Member Survey on Inclusivity
About Us
About Us
Strategic Plan
Board of Directors
Committees
Awards
Staff
Careers
Contact
Search
Donate
Login
Conferences & Webinars
Conferences & Webinars
Upcoming Conferences & Webinars
Past Conferences & Webinars
WCLC 2024
Research & Education
Research & Education
Publications, Resources & Guidelines
Journals
Journals
Journal of Thoracic Oncology
JTO Clinical and Research Reports (JTO CRR)
IASLC Reviewer Workshop
Lung Cancer 360
Research Projects
Research Projects
Staging Project
IASLC Global Survey on Biomarker Testing in Lung Cancer 2024 Update
IASLC Neoadjuvant Therapy in Lung Cancers Initiatives
IASLC Atlas of Molecular Testing for Targeted Therapy in Lung Cancer
ELIC
Early-Career Opportunities
News
News
ILCN
Press Releases
Lung Cancer Considered Podcast
Membership
Membership
Become a Member
Renew Your Membership
Partner Society Membership Offers
Patient Advocacy
Patient Advocacy
STARS
Advocacy Partner Spotlight
Lung Cancer Awareness Month 2023 Highlights
Foundation
Foundation
Donor Recognition
Research Grant Program
Grant Recipient Spotlights
Research Grant Recipients
Search
Fulltext search
Fulltext search
Search
Displaying 37 - 48 items out of 75 results
ILCN article
Patient Advocacy in 2023: A Look Back at Advocacy Efforts, Patient Concerns
ILCN article
Words Matter: Coping with Misinformation in Healthcare
ILCN article
Nivolumab Boosted Survival in Relapsed Mesothelioma
ILCN article
KEYNOTE-598: Dual PD-1 and CTLA-4 Checkpoint Blockade Confers No Therapeutic Benefit Beyond PD-1 Blockade Alone in PD-L1–Positive NSCLC
ILCN article
LCMC3 Findings Indicate Neoadjuvant Atezolizumab Safe, Efficacious in Resectable Stage IB-IIIB NSCLC
ILCN article
Genetically Tailored Treatment Approach Did Not Improve Survival in Stage II-III NSCLC
ILCN article
Pembrolizumab Considered for Second Tissue-Agnostic Cancer Indication
ILCN article
New FDA Commissioner Confirmed
ILCN article
Dr. Richard Pazdur Discusses Project Facilitate and the Expanded-Access Program
ILCN article
NCI Director Dr. Norman E. Sharpless Discusses 2019 Budget Plans During Social Media Event
ILCN article
FDA Approval Processes in the Era of Targeted Therapies: A Conversation with Dr. Richard Pazdur
ILCN article
NCI Corner: Racial Differences in the Transcriptomes of Lung Tumors
Pagination
First
First page
‹
Previous page
1
2
3
4
5
6
7
›
Next page
Last
Last page